Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Average Rating of “Moderate Buy” from Analysts

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has received a consensus rating of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $55.2857.

Several research firms have recently commented on KNSA. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Canaccord Genuity Group assumed coverage on shares of Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They set a “buy” rating and a $62.00 price target on the stock. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Finally, Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, CFO Mark Ragosa sold 17,845 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $43.28, for a total value of $772,331.60. Following the transaction, the chief financial officer directly owned 12,086 shares in the company, valued at $523,082.08. The trade was a 59.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Barry D. Quart sold 2,690 shares of the company’s stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $45.00, for a total value of $121,050.00. Following the completion of the transaction, the director directly owned 12,546 shares of the company’s stock, valued at approximately $564,570. This trade represents a 17.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 48,605 shares of company stock worth $2,122,646. Insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its stake in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. purchased a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth $31,000. USA Financial Formulas purchased a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth $32,000. Smartleaf Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth about $36,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth about $41,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $48.82 on Friday. Kiniksa Pharmaceuticals International has a 1-year low of $18.25 and a 1-year high of $49.33. The company’s fifty day simple moving average is $45.40 and its 200-day simple moving average is $41.77. The stock has a market capitalization of $3.74 billion, a PE ratio of 65.97 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, February 24th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). The company had revenue of $202.13 million during the quarter, compared to the consensus estimate of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.Kiniksa Pharmaceuticals International’s revenue for the quarter was up 65.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.12) earnings per share. As a group, research analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.